Skip to main content
SpringerLink
Log in

Clinical Use of Antiviral Drugs

  • Book
  • © 1988

Overview

Editors:
  1. Erik Clercq

    1. Rega Institute for Medical Research, Katholieke Universiteit Leuven, Belgium

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

Part of the book series: Developments in Medical Virology (DIMV, volume 3)

This is a preview of subscription content, log in via an institution to check access.

Access this book

Log in via an institution
eBook USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Other ways to access

Licence this eBook for your library

Institutional subscriptions

Table of contents (22 chapters)

  1. Front Matter

    Pages i-xvii
    Download chapter PDF

  2. Clinical Use of Antiviral Drugs

    • B. E. Juel-Jensen
    Pages 1-13

  3. Idoxuridine or How It All Began

    • W. H. Prusoff
    Pages 15-24

  4. The Treatment of Herpetic Eye Infections with Trifluridine and Other Anti-Virals

    • H. E. Kaufman
    Pages 25-38

  5. Treatment (Bromovinyldeoxyuridine) of Herpetic Eye Infections

    • P. C. Maudgal, E. De Clercq
    Pages 39-48

  6. Diagnosis and Treatment of Herpes Simplex Encephalitis

    • Richard J. Whitley
    Pages 49-66

  7. Treatment of Herpes Simplex Labialis

    • S. L. Spruance
    Pages 67-86

  8. Treatment of Herpes Genitalis

    • S. L. Sacks
    Pages 87-114

  9. Treatment of Herpes Simplex Virus Infections in Immunosuppressed Patients

    • R. Saral, P. Lietman
    Pages 115-125

  10. Antiviral Therapy of Varicella-Zoster Virus Infections

    • J. Englund, H. H. Balfour Jr.
    Pages 127-143

  11. Treatment (Bromovinyldeoxyuridine) of Varicella-Zoster Virus Infections

    • S. Shigeta, E. De Clercq
    Pages 145-157

  12. Therapy and Prevention of Cytomegalovirus Infections

    • Paul R. Skolnik, Martin S. Hirsch
    Pages 159-194

  13. The Prophylaxis of Herpes Group Infections in Patients with Haematological Malignancy

    • H. G. Prentice, I. M. Hann
    Pages 195-206

  14. Resistance of Herpes Viruses to Nucleoside Analogues — Mechanisms and Clinical Importance

    • C. Crumpacker
    Pages 207-222

  15. Clinical Use of Foscarnet (Phosphonoformate)

    • B. Öberg, S. Behrnetz, B. Eriksson, H. Jozwiak, A. Larsson, J. O. Lernestedt et al.
    Pages 223-240

  16. Prophylaxis and Treatment of Rhinovirus Infections

    • D. A. J. Tyrrell, W. Al-Nakib
    Pages 241-276

  17. Rimantadine and Amantadine in the Prophylaxis and Therapy of Influenza A

    • Raphael Dolin
    Pages 277-287

  18. Ribavirin Aerosol Treatment of Influenza, Respiratory Syncytial and Parainfluenza Virus Infections of Man

    • V. Knight, B. Gilbert
    Pages 289-304

  19. Antiviral Therapy of Highly Pathogenic Viral Diseases

    • J. B. McCormick, S. P. Fisher-Hoch
    Pages 305-315

  20. Perspectives in the Use of Antiviral Agents for Prevention and Treatment of Respiratory Virus Infections

    • S. J. Sperber, F. G. Hayden
    Pages 317-340
Back to top

Keywords

About this book

Antiviral chemotherapy has come of age, and, after an initial slow pro­ gress, the development of new antiviral agents has proceeded at a more rapid pace and the perspectives for their clinical use have increased considerably. Now, 25 years after the first antiviral assay (idoxuridine) was introduced in the clinic, it is fitting to commemorate the beginning of the antivirals' era. In its introductory chapter B.E. Juel-Jensen touches on what may be con­ sidered as five of the most fundamental requirements of an antiviral drug : efficacy, relative non-toxicity, easy solubility, ready availability and rea­ sonable cost. Surely, the antiviral drugs that have so far been used in the clinic could still be improved upon as one or more of these five essential demands are concerned. How is all began is narrated by W.H. Prusoff. The first antiviral drugs to be used in humans were methisazone and idoxuridine, the former, which is now of archival interest, in the prevention of smallpox, the latter, which was approved for clinical use in the United States in 1962, for the topical treatment of herpetic keratitis. In terms of potency, also because of solubility reasons, idoxuridine has been superseded by trifluridine in the topical treatment of herpes simplex epithelial keratitis. H.E. Kaufman did not find trifluridine or acyclovir ef­ fective in the treatment of deep stromal keratitis or iritis and he reckons that other antiviral drugs (i.e. bromovinyldeoxyuridine) would not be effec­ tive either.

Editors and Affiliations

  • Rega Institute for Medical Research, Katholieke Universiteit Leuven, Belgium

    Erik Clercq

Bibliographic Information

  • Book Title: Clinical Use of Antiviral Drugs

  • Editors: Erik Clercq

  • Series Title: Developments in Medical Virology

  • DOI: https://doi.org/10.1007/978-1-4613-1715-9

  • Publisher: Springer New York, NY

  • eBook Packages: Springer Book Archive

  • Copyright Information: Martinus Nijhoff Publishing, Boston 1988

  • Hardcover ISBN: 978-0-89838-357-7Published: 31 January 1988

  • Softcover ISBN: 978-1-4612-8966-1Published: 09 February 2012

  • eBook ISBN: 978-1-4613-1715-9Published: 06 December 2012

  • Edition Number: 1

  • Number of Pages: XVIII, 414

  • Topics: Virology

Publish with us

Policies and ethics

Back to top

Search

Navigation